GLOW Peptide Blend: GHK-Cu, BPC-157, and TB-500, and How KLOW Differs

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to the GLOW or KLOW peptide blends. No ingredient in either blend is FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Key takeaways

• What it is: GLOW is an injectable blend of GHK-Cu, BPC-157, and TB-500. KLOW is the same blend plus KPV.
• Evidence: Each ingredient has been studied on its own, mostly in cell culture and animal models. No human trial of either blend exists.
• FDA status: None of the ingredients is FDA-approved, and none is eligible for 503A compounding in injectable form as of September 2026.
• Availability: Products sold as GLOW or KLOW are research chemicals labeled not for human use. Superpower does not offer or sell them.
• Testing: Standard baseline markers give context on liver, kidney, and blood health. They do not measure what a peptide is doing.

What is the GLOW peptide blend?

GLOW is a product name for an injectable blend of three peptides: GHK-Cu, BPC-157, and TB-500. Vendors and clinic pages that use the name describe the same trio, and each ingredient is a separate compound with its own research history.

No regulator, pharmacopeia, or clinical trial defines GLOW as a single molecule or a standard formulation. The name is a market label, so doses, ratios, and purity vary by seller. The sections below take the ingredients one at a time, because the evidence exists only at that level.

GLOW vs. KLOW

KLOW is GLOW plus KPV, which makes it a four-peptide blend. KPV is a short peptide that the FDA lists among substances nominated for compounding, and its regulatory story is covered in the status section below. The other three ingredients are identical in both products.

Because KLOW adds an ingredient, everything true of GLOW applies to KLOW, and KLOW carries one more compound with its own unanswered questions. No study tests either blend, so nothing here supports regarding KLOW as an upgrade.

GHK-Cu: the copper tripeptide

GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper, and it has the longest research record of the three. The first report, in 1973, found that the tripeptide increases survival of normal liver cells, and a 2008 review of tissue remodeling summarized the decades of work that followed.

The skin-related findings are mostly in vitro or animal work. In a rat wound-chamber study, GHK-Cu raised collagen content in a concentration-dependent way, along with type I and III collagen messenger RNA. In rats with ischemic wounds, a topical GHK-Cu gel reduced wound area by 64.5% at day 13, against 45.6% for vehicle and 28.2% for wounds left alone. A 2018 review added gene-expression data on pathways GHK regulates, which describe what GHK-Cu changes in cells rather than what it does for a person.

Human data on GHK-Cu comes from topical use, and it is thin. A randomized trial of topical copper tripeptide on CO2 laser-resurfaced skin, in the 13 patients who completed it, found no statistically significant differences between groups on objective assessment of erythema, wrinkles, or overall skin quality, though patient-rated skin quality favored GHK-Cu. A 2025 review of topical GHK found clinical studies surprisingly scarce and regards skin permeability as an open question. This guide cites no trial of injected GHK-Cu.

BPC-157: the gastric-derived pentadecapeptide

BPC-157 is a synthetic 15-amino-acid fragment of a protein found in human gastric juice. In early rat ulcer models from the group that discovered it, BPC 157 protected against stress, cysteamine, and ethanol lesions. The same group described the 15-amino-acid fragment as thought to be essential to the larger protein's activity.

Proposed mechanisms center on blood vessels and connective tissue. In isolated rat aorta, BPC 157 produced an endothelium-dependent vasodilatory effect tied to nitric oxide signaling. Another study linked it to VEGFR2 upregulation and new vessel growth in chick-embryo and rat hind-limb models and in cultured human endothelial cells. In cultured rat tendon fibroblasts, it increased FAK and paxillin phosphorylation, a pathway tied to cell migration. These are animal and cell findings, and none has been confirmed as a mechanism in people.

The human evidence is close to empty. A 2025 systematic review of orthopaedic sports-medicine literature found 36 studies, 35 preclinical and one clinical, and no controlled human trial among them. The one human report is an uncontrolled chart review of 16 knee-injection patients, with pain outcomes collected by phone survey. The same review reported a half-life under 30 minutes from animal studies, and it found only one registered human trial, a phase I study of unknown status. An independent 2019 review also noted that only a handful of research groups have studied BPC-157 in depth, mostly in small rodent models.

TB-500: the thymosin beta-4 fragment

Thymosin beta-4 is a 43-amino-acid protein that a 2005 review described as an actin-sequestering protein with roles in repair. TB-500 is not that protein. Its key ingredient is an acetylated copy of residues 17 to 23, the stretch of thymosin beta-4 tied to actin binding, cell migration, and wound repair. Doping-control labs characterized the fragment in TB-500 in 2012 because the product was suspected of use in sport, and one lab built a test for its misuse in horses.

The case for the fragment starts with a 2003 mouse study. Full-length thymosin beta-4 accelerated dermal wound repair in diabetic and aged mice, and a seven-amino-acid peptide copying its actin-binding domain promoted repair in the aged mice. That result is a reason to study the fragment, and it stops there. A 2010 review mapped thymosin beta-4's activities to several active sites in short sequences, and TB-500 carries only one of them.

The strongest animal work belongs to the full protein. Full-length thymosin beta-4 improved cardiac function after coronary ligation in mice, yet a later study in mice and pigs credited the C-terminal AGES domain for the post-ischemic cardiac benefit, and TB-500 does not contain it. The human trial data belong to the full protein too: an eye-drop trial of full-length thymosin beta-4 in 18 patients narrowly missed its primary endpoint, though some secondary measures favored the active eye drops. A 2026 scoping review found musculoskeletal claims for TB-500 and similar peptides unsubstantiated by current human trials.

What the evidence says about the blend itself

No study, in humans or animals, tested GHK-Cu, BPC-157, and TB-500 together, and none tested KPV alongside them. The closest is a 2026 rat Achilles-tendon study of BPC-157 and TB-500, where the combination added no benefit over either alone. Most findings above are animal or cell-culture results. The human data are thin: small topical GHK-Cu skin studies, one with a null objective result, an uncontrolled 16-patient BPC-157 chart review, and eye-drop work on full-length thymosin beta-4.

A blend also raises questions no single-ingredient paper answers: whether the peptides interact, whether the mixture is stable, and whether the ratios sold match the ratios studied. Claims that GLOW works for skin, recovery, or repair outrun the published evidence, and this guide makes none.

Join 150,000+ others building better health

Get the science behind better health, every week.

SubscribeSigning up...

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

FDA status of GLOW and KLOW ingredients

As of September 2026, an injectable GLOW or KLOW blend is not eligible for 503A compounding. None of its ingredients, in injectable form, is on the 503A bulks list or in Category 1.

BPC-157, TB-500, injectable GHK-Cu, and KPV appear in FDA's table of substances nominated but withdrawn from compounding consideration. FDA announced on April 15, 2026 that it would remove peptides from its Category 2 list of significant safety risks. The removal took effect around April 22, 2026, because the nominators withdrew their nominations. That was not an FDA finding that the substances are safe, and it did not make them eligible. A withdrawn substance stays out of 503A compounding unless FDA adds it to the bulks list through rulemaking or places it in Category 1, and none of them is in Category 1 on the May 14, 2026 list.

GHK-Cu and KPV specifics

GHK-Cu is a partial exception. Non-injectable GHK-Cu is in Category 1, and FDA's list marks the injectable route as the withdrawn one. Topical GHK-Cu is a different product from an injectable GLOW or KLOW blend, and this guide does not cover it.

The FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, and TB-500 at its July 23 and 24, 2026 meeting. It voted 8-6 in favor of including each on the bulks list, according to a law-firm summary of the votes. Those votes are non-binding, and FDA must still complete rulemaking, which may run into 2027 or longer. Until it does, the three are not on the list. FDA also plans a further committee meeting before the end of February 2027 that includes GHK-Cu.

Products sold as GLOW or KLOW come from the research-chemical market and are labeled not for human use. Such products carry no assurance of purity, potency, or sterility, and none has FDA approval for any use. Superpower does not sell, prescribe, or facilitate GLOW or KLOW.

IMPORTANT SAFETY INFORMATION

GLOW and KLOW are not approved by the FDA for any medical use. They are research-chemical blends, and products sold under those names are labeled not for human use.

GLOW contains GHK-Cu, BPC-157, and TB-500. KLOW adds KPV. The research on these ingredients is preliminary and comes mostly from cell-culture and animal studies. No human trial of either blend exists, and their safety and effectiveness in people have not been established.

Superpower does not offer, sell, prescribe, or facilitate GLOW, KLOW, BPC-157, TB-500, KPV, or injectable GHK-Cu. Evidence is preliminary, and no safety or effectiveness claims are made.

Products sold through unregulated channels have no verified purity, potency, or sterility. This page is educational and does not constitute medical advice. Talk with a licensed clinician about any question about your health.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to the GLOW or KLOW peptide blends. No ingredient in either blend is FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.